Prognostic effect of programmed death-ligand 1 (PD-L1) in ovarian cancer: a systematic review, meta-analysis and bioinformatics study
出版年份 2019 全文链接
标题
Prognostic effect of programmed death-ligand 1 (PD-L1) in ovarian cancer: a systematic review, meta-analysis and bioinformatics study
作者
关键词
-
出版物
Journal of Ovarian Research
Volume 12, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2019-04-30
DOI
10.1186/s13048-019-0512-6
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women
- (2018) Anne M. Mills et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY
- Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer
- (2018) Maureen L. Drakes et al. Journal of Ovarian Research
- The BRCA1 Methylation and PD-L1 Expression in Sporadic Ovarian Cancer
- (2018) Xinxin Zhu et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Prognostic value of tumor PD-L1 expression combined with CD8 + tumor infiltrating lymphocytes in high grade serous ovarian cancer
- (2017) Qiaohong Wang et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- PD-L1
- (2017) Anthousa Kythreotou et al. JOURNAL OF CLINICAL PATHOLOGY
- Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma
- (2017) Jun Zhu et al. Journal of Gynecologic Oncology
- Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer
- (2017) Emeka K Enwere et al. MODERN PATHOLOGY
- The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC)
- (2017) Nobumoto Tomioka et al. Breast Cancer
- Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy
- (2017) Mengjiao Li et al. Journal of Ovarian Research
- Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma
- (2017) Hae Il Jung et al. Cancer Research and Treatment
- PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity
- (2017) Maria Gato-Cañas et al. Cell Reports
- Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC)
- (2016) S J L Mesnage et al. ANNALS OF ONCOLOGY
- Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian Cancer
- (2016) Jayanta Chatterjee et al. CLINICAL CANCER RESEARCH
- PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer
- (2016) John R. Webb et al. GYNECOLOGIC ONCOLOGY
- Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status
- (2016) Yoon Jin Cha et al. LUNG CANCER
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
- (2016) Weiping Zou et al. Science Translational Medicine
- IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer
- (2015) K Abiko et al. BRITISH JOURNAL OF CANCER
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
- (2015) Nan Chen et al. Journal of Thoracic Oncology
- Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma
- (2015) Silvia Darb-Esfahani et al. Oncotarget
- Blockade of the B7-H1/PD-1 Pathway as a Basis for Combination Anticancer Therapy
- (2014) Mario Sznol CANCER JOURNAL
- Synergistic effects of IL-4 and TNFα on the induction of B7-H1 in renal cell carcinoma cells inhibiting allogeneic T cell proliferation
- (2014) Dagmar Quandt et al. Journal of Translational Medicine
- Overview: Progression-Free Survival as an Endpoint in Clinical Trials with Solid Tumors
- (2013) R. L. Korn et al. CLINICAL CANCER RESEARCH
- Interferon-induced programmed death-ligand 1 (PD-L1/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment
- (2013) Holger Krönig et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients
- (2012) Balázs Győrffy et al. ENDOCRINE-RELATED CANCER
- Detection of novel biomarkers for ovarian cancer with an optical nanotechnology detection system enabling label-free diagnostics
- (2012) Simon Kaja JOURNAL OF BIOMEDICAL OPTICS
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- (2012) J. M. Taube et al. Science Translational Medicine
- Ovarian Low-grade and High-grade Serous Carcinoma
- (2009) Russell Vang et al. ADVANCES IN ANATOMIC PATHOLOGY
- Comment on: heterogeneity in meta-analysis should be expected and appropriately quantified
- (2009) M. D. Coory INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. PLOS MEDICINE
- Blinded Independent Central Review of Progression-Free Survival in Phase III Clinical Trials: Important Design Element or Unnecessary Expense?
- (2008) Lori E. Dodd et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More